Last year, as I remember it, Jeffrey dominated the
Post# of 15624
(Total Views: 268)
Posted On: 01/09/2018 2:29:52 PM
Last year, as I remember it, Jeffrey dominated the OWCP presentation at the Wall St. Conference, in part because Ziv was a terrible speaker, but also because he had his own agenda, and he used the company's sponsorship to advance it. I would hope that this year our speaker gets 100% of the time in the presentation, and is also generally available to investors who are attending.
I really can't say what news they'll announce, but IMHO it would be positive if he could just confirm much of what is shown in the corporate presentation timeline, or even presented a revised timeline. To my knowledge, we have no confirmation that the fibromyalgia trial has actually begun, though shown to begin last quarter. We ought to be at the point where they can with a reasonable degree of accuracy say when the Phase 1 psoriasis cream trial should end, if it hasn't completed by the conference.
My point is, he could confirm much that's shown in the presentation that hasn't been confirmed, and I would hope that by then the company has a new presentation that would give us all an indication of what he'll be discussing.
If their is any doubt, I've got to believe the company's major reason for being at this conference is in some way to raise funds. Certainly dilution is possible, but other possibilities will also exist including identifying companies who might in the future be selling OWCP's products and are willing to pay for those rights to do so.
I certainly don't know that the company's intent is to initiate sales immediately after the Phase 1 ends. It's possible they want to take it a step further and do Phase 2, a small trial which could be done quickly, but which would truly show efficacy. A sales program based on some proof of efficacy would be stronger than saying try it and give us your feedback to gain anecdotal proof of efficacy. I know this would move sale revenue off till at least late this year, but truly it would be more like a Biotech approach.
We all know others have creams that have no trials, they are viewed as safe because they contain under a specific percentage of the cannabis component. Our cream may, or may not have the same percentage, or more, it may also contain other cannabis components that the others don't, the difference is, it will have been proven safe, whereas the others simply use guidance that says that if they limit what's in the cream to XXX they can market it with no further proof. Our cream should be far more effective.
Gary
I really can't say what news they'll announce, but IMHO it would be positive if he could just confirm much of what is shown in the corporate presentation timeline, or even presented a revised timeline. To my knowledge, we have no confirmation that the fibromyalgia trial has actually begun, though shown to begin last quarter. We ought to be at the point where they can with a reasonable degree of accuracy say when the Phase 1 psoriasis cream trial should end, if it hasn't completed by the conference.
My point is, he could confirm much that's shown in the presentation that hasn't been confirmed, and I would hope that by then the company has a new presentation that would give us all an indication of what he'll be discussing.
If their is any doubt, I've got to believe the company's major reason for being at this conference is in some way to raise funds. Certainly dilution is possible, but other possibilities will also exist including identifying companies who might in the future be selling OWCP's products and are willing to pay for those rights to do so.
I certainly don't know that the company's intent is to initiate sales immediately after the Phase 1 ends. It's possible they want to take it a step further and do Phase 2, a small trial which could be done quickly, but which would truly show efficacy. A sales program based on some proof of efficacy would be stronger than saying try it and give us your feedback to gain anecdotal proof of efficacy. I know this would move sale revenue off till at least late this year, but truly it would be more like a Biotech approach.
We all know others have creams that have no trials, they are viewed as safe because they contain under a specific percentage of the cannabis component. Our cream may, or may not have the same percentage, or more, it may also contain other cannabis components that the others don't, the difference is, it will have been proven safe, whereas the others simply use guidance that says that if they limit what's in the cream to XXX they can market it with no further proof. Our cream should be far more effective.
Gary
(0)
(0)